-
Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Cancer letters 20150828
-
Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
Cancer chemotherapy and pharmacology 20121201
-
Eribulin mesylate in patients with refractory cancers: a Phase I study.
Investigational new drugs 20121001
-
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Clinical cancer research : an official journal of the American Association for Cancer Research 20120901
-
Stability of the ready-to-use solutions of eribulin for intravenous infusion.
Annales pharmaceutiques francaises 20120901
-
Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
Expert opinion on drug safety 20120701
-
Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Clinical therapeutics 20120701
-
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.
Investigational new drugs 20120601
-
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology 20120601
-
Eribulin: a novel cytotoxic chemotherapy agent.
The Annals of pharmacotherapy 20120601
-
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.
Annals of oncology : official journal of the European Society for Medical Oncology 20120501
-
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.
Cancer 20120501
-
Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120501
-
Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
Anticancer research 20120501
-
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
Cancer treatment reviews 20120401
-
Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a 'physician's choice' control arm in a randomized approval trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 20120315
-
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120301
-
Eribulin -- a review of preclinical and clinical studies.
Critical reviews in oncology/hematology 20120201
-
Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
Drug metabolism and disposition: the biological fate of chemicals 20120201
-
Eribulin: Heavily pretreated breast cancer: uncertain advantages, excessive adverse effects.
Prescrire international 20120201
-
Concise and highly stereoselective synthesis of the C20-C26 building block of halichondrins and Eribulin.
Organic letters 20120120
-
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
Clinical lung cancer 20120101
-
Eribulin mesylate for the treatment of late-stage breast cancer.
Expert opinion on pharmacotherapy 20111201
-
Eribulin mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 20111101
-
Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?
Advances in therapy 20111101
-
[Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20111101
-
Eribulin in soft-tissue sarcomas.
The Lancet. Oncology 20111001
-
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
The Lancet. Oncology 20111001
-
Natural product drug discovery: the successful optimization of ISP-1 and halichondrin B.
Current opinion in chemical biology 20110801
-
Eribulin.
Drugs 20110709
-
Interactions of halichondrin B and eribulin with tubulin.
Journal of chemical information and modeling 20110627
-
Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice.
Cancer research 20110601
-
Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110501
-
[Eribulin: a new therapeutic option in intensely pretreated metastatic cancer of the breast?].
Bulletin du cancer 20110501
-
Eribulin mesylate (Halaven) for breast cancer.
The Medical letter on drugs and therapeutics 20110418
-
Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.
Investigational new drugs 20110401
-
Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells.
Xenobiotica; the fate of foreign compounds in biological systems 20110401
-
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility.
Bioorganic & medicinal chemistry letters 20110315
-
Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model.
Bioorganic & medicinal chemistry letters 20110315
-
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
Bioorganic & medicinal chemistry letters 20110315
-
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Lancet (London, England) 20110312
-
EMBRACE, eribulin, and new realities of advanced breast cancer.
Lancet (London, England) 20110312
-
Eribulin mesylate.
Nature reviews. Drug discovery 20110301
-
Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
Future oncology (London, England) 20110301
-
Nontaxane microtubule dynamics inhibitors.
Clinical advances in hematology & oncology : H&O 20110301
-
The place for eribulin in the treatment of metastatic breast cancer.
Current oncology reports 20110201
-
Editorial: Marine Natural Products themed issue.
Natural product reports 20110201
-
Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions.
Cancer research 20110115
-
Eribulin approved for advanced breast cancer.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110101
-
New drugs: Ceftaroline fosamil, pegloticase, and eribulin mesylate.
Journal of the American Pharmacists Association : JAPhA 20110101
-
Complex synthesis yields breast-cancer therapy.
Nature 20101202
-
Advances in therapy: eribulin improves survival for metastatic breast cancer.
Anti-cancer drugs 20101101
-
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100901
-
Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer.
Drugs of today (Barcelona, Spain : 1998) 20100901
-
Eribulin mesylate for the treatment of breast cancer.
Expert opinion on pharmacotherapy 20100601
-
Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
Clinical breast cancer 20100401
-
Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability.
Biochemistry 20100216
-
[New drugs in metastatic castration-resistant prostate cancer].
Bulletin du cancer 20100101
-
Second generation synthesis of C27-C35 building block of E7389, a synthetic halichondrin analogue.
Organic letters 20091015
-
Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation.
Biochemistry 20090825
-
The halichondrins and E7389.
Chemical reviews 20090701
-
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090620
-
Eribulin: rediscovering tubulin as an anticancer target.
Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
-
Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
-
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
-
Novel anti-tubulin cytotoxic agents for breast cancer.
Expert review of anticancer therapy 20090201
-
A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081115
-
Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.
Cancer chemotherapy and pharmacology 20080901
-
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase.
Molecular cancer therapeutics 20080701
-
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
Seminars in oncology 20080401
-
Promising novel cytotoxic agents and combinations in metastatic prostate cancer.
Cancer journal (Sudbury, Mass.) 20080101
-
Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
Current opinion in investigational drugs (London, England : 2000) 20071201
-
Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.
Molecular pharmacology 20061201
-
Scientists are searching the seas for cancer drugs.
Journal of the National Cancer Institute 20060517
-
Chemistry. The renaissance of natural products as drug candidates.
Science (New York, N.Y.) 20051021
-
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth.
Molecular cancer therapeutics 20050701
-
Macrocyclic ketone analogues of halichondrin B.
Bioorganic & medicinal chemistry letters 20041115
-
In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B.
Cancer research 20010201
